Stock of the Day

October 13, 2020

CareDx (CDNA)

$48.97
-$1.14 (-2.3%)
Market Cap: $2.59B

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Trend

CareDx, Inc. (NASDAQ: CDNA) shares increased as investors responded to a strong second-quarter 2026 report and an upgraded full-year revenue outlook. Trading volume was also well above average, indicating significant investor attention following the results.

  • CareDx reported second-quarter adjusted earnings of $0.37 per share, exceeding the $0.22 analyst consensus and improving from $0.10 in the year-ago quarter. CareDx Beats Q2 Earnings and Revenue Estimates
  • Revenue rose 52.2% year over year to $131.95 million, well above the $113.83 million consensus estimate. The sizable revenue beat signals continued demand growth and operating momentum. CareDx Q2 Non-GAAP Earnings and Revenue Outlook
  • The company raised its 2026 revenue outlook to $490 million-$500 million, substantially above the roughly $455.7 million analyst expectation. The guidance increase is likely the most important catalyst for the stock because it points to stronger full-year growth than previously anticipated. CareDx Announces Second Quarter 2026 Financial Results
  • Management’s earnings call and presentation provided additional detail on the quarter and updated outlook, reinforcing the market’s focus on revenue growth and execution through the remainder of 2026. CareDx Q2 2026 Earnings Call Transcript
  • Despite the adjusted earnings beat, CareDx continued to report a negative net margin, suggesting profitability remains a risk while the company scales its business. CareDx Q2 Earnings Snapshot
← Previous Stock of the DayNext Stock of the Day →